News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Swiss Approve Novartis International AG Drug For Blindness
August 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Policy
FDA turns to old drugs to address new diseases, persistent medical needs
May 12, 2026
·
2 min read
·
Tristan Manalac
Government
Makary’s reported FDA removal could be ‘broad positive’ for biopharma
May 11, 2026
·
3 min read
·
Tristan Manalac
Approvals
Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher
May 11, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
May 8, 2026
·
2 min read
·
Tristan Manalac